Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 27, 2026
Celestica (CLS) Q2 2026 Earnings: Watching for Reaffirmation After -35% Drop

Celestica (CLS) Q2 2026 Earnings: Watching for Reaffirmation After -35% Drop

Key Takeaways

  • Celestica reports Q2 2026 results after market close on Monday, July 27, with a conference call scheduled for 8:00 a.m. ET on July 28.
  • Consensus estimates point to adjusted EPS of approximately $2.29 on revenue of $4.35 billion, representing year-over-year growth of roughly 65% and 50%, respectively.
  • Company-issued guidance calls for revenue of $4.15 billion to $4.45 billion and adjusted EPS of $2.14 to $2.34, with an adjusted operating margin of approximately 8.0% at the midpoint.
  • CLS shares have fallen roughly 35% from their June 2026 high of $474.03, closing at $305.28 on July 24, intensifying scrutiny on whether Q2 results can reaffirm the AI-driven growth narrative.
  • Investor focus centers on the Connectivity and Cloud Solutions (CCS) segment, which surged 76% year-over-year in Q1 2026, driven by hyperscaler demand for networking and compute infrastructure.
  • Full-year 2026 guidance was raised to $19.0 billion in revenue and $10.15 in adjusted EPS following the Q1 report, setting a high bar for the second-half trajectory.

Why This Earnings Report Matters

Celestica's Q2 2026 report arrives at a critical juncture for the company and the broader AI infrastructure theme. The Toronto-based electronics manufacturing services provider has become one of the more direct plays on hyperscaler spending for data centers, with its CCS segment delivering strong growth over the past year. After lifting its full-year 2026 outlook to $19.0 billion in revenue in April, the company now needs to show that the raised targets remain achievable amid questions about the durability of AI-related capex. With CLS shares down 35% from the June peak, the upcoming print offers a timely check on enterprise and cloud demand trends.

Consensus Estimates and Company Guidance

Wall Street expectations are elevated heading into the report. The Zacks Consensus Estimate calls for adjusted EPS of $2.29 on revenue of $4.35 billion, which would represent year-over-year growth of about 65% on the bottom line and 50% on the top line. Celestica's own guidance, provided with the Q1 results on April 27, projects revenue between $4.15 billion and $4.45 billion and adjusted EPS between $2.14 and $2.34, with adjusted operating margin expected near 8.0% at the midpoint.

In Q1 2026 the company posted revenue of $4.05 billion and adjusted EPS of $2.16, beating the high end of its EPS range. The CCS segment generated $3.24 billion, up 76% year-over-year, while the ATS segment contributed $0.81 billion and was essentially flat. Analysts expect CCS to continue driving growth in Q2, with segment revenue consensus around $3.58 billion. Over the past four quarters CLS has delivered an average earnings surprise of roughly 8%.

To compare CLS with peers in the space, I also checked this using Tickeron’s AI Screener to see how the stock stacks up on key metrics.

Stock Performance and Market Sentiment

Investor caution is evident in the recent price action. CLS closed at $305.28 on July 24, down 35% from its 52-week high of $474.03 reached on June 2. The decline reflects both a broader pullback in high-momentum AI names and specific concerns, including the planned increase in 2026 capital expenditures to approximately $1 billion from an earlier $400 million budget. This has raised questions about free cash flow and margin trends in the near term.

The pullback has brought the forward P/E ratio down to around 32 times, below earlier levels above 40 but still above the historical average. Customer concentration is another point of focus, with three customers accounting for roughly 36%, 15%, and 12% of revenue. Any signs of softening demand from these accounts could weigh on the stock, while a beat-and-raise outcome that supports the $19.0 billion annual target could provide relief, especially given the current technical setup.

Forward Outlook and Areas to Monitor

Beyond the headline numbers, several forward indicators will shape the outlook for the balance of 2026 and into 2027.

Full-Year Guidance. The key question is whether management reaffirms, raises, or reduces the $19.0 billion revenue and $10.15 adjusted EPS targets. The Street has already incorporated the April increase, so any downward revision, particularly in the CCS enterprise vertical, would likely draw scrutiny.

CCS Segment and Hyperscaler Trends. The CCS segment remains the main growth driver. Commentary on order pipelines, 800G Ethernet switch adoption, and new networking wins will be closely watched. With major hyperscalers such as Google targeting around $80 billion in annual capex, the ability to convert demand into backlog matters. Investors will also note any updates on supply chain or production timeline risks highlighted in the Q1 call.

Margin and Capex Dynamics. The ramp in capital expenditures to $1 billion is substantial. The market will look for evidence that adjusted operating margin can hold near the 8.0% target and that the $500 million free cash flow target for the year remains intact.

ATS Segment. While secondary to CCS, any stabilization or improvement in HealthTech, industrial, and capital equipment markets could broaden the growth story and lessen dependence on the CCS segment.

My Approach to Research

When preparing for earnings like this one, I frequently use Tickeron’s AI Screener to quickly filter names in the AI infrastructure space by technical patterns, fundamentals, and trend strength. It helps surface comparable ideas without spending hours on manual screens and has become a regular part of my workflow for staying on top of momentum names.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CLS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


CLS sees MACD Histogram crosses below signal line

CLS saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on August 10, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on August 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLS as a result. In of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

CLS moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CLS broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CLS entered a downward trend on July 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLS's RSI Indicator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CLS advanced for three days, in of 368 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CLS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLS's P/B Ratio (17.271) is slightly higher than the industry average of (6.729). P/E Ratio (36.403) is within average values for comparable stocks, (99.051). CLS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.326). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.605) is also within normal values, averaging (5.582).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Corning (NYSE:GLW), Universal Display Corp (NASDAQ:OLED).

Industry description

The Electronic Components industry produces electronic equipment for industries and consumer electronics products, such as mobile devices, televisions, and circuit boards. TE Connectivity Ltd, for example, is a company that designs and manufactures connectivity and sensor products for harsh environments in various industries, such as automotive, industrial equipment, aerospace, and oil & gas. Another major player, Corning Inc., makes advanced optics including end-to-end fiber and wireless solutions for communications networks along with various other technologies catering to industrial and scientific applications.

Market Cap

The average market capitalization across the Electronic Components Industry is 14.04B. The market cap for tickers in the group ranges from 669 to 209.56B. APH holds the highest valuation in this group at 209.56B. The lowest valued company is MMATQ at 669.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Components Industry was 5%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 21%. GAUZ experienced the highest price growth at 70%, while WBX experienced the biggest fall at -7%.

Volume

The average weekly volume growth across all stocks in the Electronic Components Industry was -34%. For the same stocks of the Industry, the average monthly volume growth was 19% and the average quarterly volume growth was -41%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 46
Price Growth Rating: 49
SMR Rating: 73
Profit Risk Rating: 65
Seasonality Score: -27 (-100 ... +100)
View a ticker or compare two or three
CLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of electronics manufacturing services

Industry ElectronicComponents

Profile
Details
Industry
Electronic Components
Address
5140 Yonge Street
Phone
+1 416 448-5800
Employees
26554
Web
https://www.celestica.com
Interact to see
Advertisement
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Gogo shares continue to trade near 52-week lows around $4, weighed down by competitive threats from Starlink and slower-than-anticipated AVANCE system upgrades. William Blair downgraded the stock to Market Perform in December 2025, citing leverage concerns and intensifying rivalry in in-flight connectivity.
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.